Exec-Edge – Page 47 – ExecEdge

OmniScience and INmune Bio Partner for Alzheimer’s Trial

OmniScience and INmune Bio Partner for Alzheimer’s Trial

By Karen Roman OmniScience and INmune Bio, Inc. (Nasdaq: INMB) said they’re using genAI in an Alzheimer’s disease trial. The AI will support the live clinical trial and is expected to increase efficiency and the probability of success, both companies...

Agendia’s MammaPrint Optimizes Breast Cancer Therapy

Agendia’s MammaPrint Optimizes Breast Cancer Therapy

  By Karen Roman Agendia, Inc. said its gene expression profiling test MammaPrint can predict extended endocrine therapy benefit for patients with early-stage breast cancer. The test helps optimizing additional therapy and can potentially improve survival, the company said. “These...

Liquidity in Private Equity at 4th Palm Beach CorpGov Forum

Liquidity in Private Equity at 4th Palm Beach CorpGov Forum

PE Edge and Exec Edge are pleased to provide complete video coverage of the fourth annual Palm Beach CorpGov Forum held on Nov. 13-14, featuring a two-day event with panels, firesides and networking receptions. The audience comprised more than 200 attendees...

PE Investing in Latin America at 4th Palm Beach CorpGov Forum

PE Investing in Latin America at 4th Palm Beach CorpGov Forum

PE Edge and Exec Edge are pleased to provide complete video coverage of the fourth annual Palm Beach CorpGov Forum held on Nov. 13-14, featuring a two-day event with panels, firesides and networking receptions. The audience comprised more than 200 attendees...

Kohl’s Revises FY Outlook, Appoints New CEO

Kohl’s Revises FY Outlook, Appoints New CEO

By Karen Roman Kohl’s Corp. (NYSE: KSS) said net sales decreased 8.8% to $3.5 billion and comparable sales declined 9.3% for the third quarter. Net income was $22 million, or $0.20 per diluted share, compared to $59 million and $0.53...

Input your search keywords and press Enter.